title: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
abstract: OBJECTIVE
  T-prolymphocytic leukemia (T-PLL) is an aggressive malignancy of mature T cells refractory to conventional chemotherapy, with a median survival duration of 7.5 months. We report here promising results with the use of a genetically reshaped human CD52 antibody, CAMPATH-1H.
  
  
  METHODS
  Fifteen patients with T-PLL, most of whom had received the purine analog deoxycoformycin (DCF), were treated with CAMPATH-1H. Results were compared with those of 25 patients treated with DCF.
  
  
  RESULTS
  Major responses occurred in 11 patients (73%) treated with CAMPATH-1H compared with 40% with DCF. Complete remissions (CRs) were documented in nine (60%) of the CAMPATH-1H cases and only three (12%) were obtained with DCF. CRs with CAMPATH-1H were durable, and re-treatment with the antibody resulted in second CRs in three relapsed patients. Two of them were successfully autografted with peripheral-blood and bone marrow stem cells collected during the first CR. Apart from first-dose reactions, infusions of CAMPATH-1H were well tolerated. However, two responding patients developed severe bone marrow aplasia that was fatal in one; the second remained moderately pancytopenic 21 weeks after stopping CAMPATH-1H therapy. The cause of this adverse effect is unknown.
  
  
  CONCLUSIONS
  CAMPATH-1H is an effective agent in T-PLL and represents a significant improvement over other types of therapy. However, CAMPATH-1H alone is not sufficient for long-term remissions, and the role of autologous stem-cell transplantation needs further investigation.
authors.affiliation: Academic Department of Hematology and Cytogenetics, Royal Marsden Hospital, London, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Pawson
authors.forename: M J
authors.initials: MJ
authors.lastname: Dyer
authors.forename: R
authors.initials: R
authors.lastname: Barge
authors.forename: E
authors.initials: E
authors.lastname: Matutes
authors.forename: P D
authors.initials: PD
authors.lastname: Thornton
authors.forename: E
authors.initials: E
authors.lastname: Emmett
authors.forename: J C
authors.initials: JC
authors.lastname: Kluin-Nelemans
authors.forename: W E
authors.initials: WE
authors.lastname: Fibbe
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: D
authors.initials: D
authors.lastname: Catovsky
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy*; D015458:Leukemia, T-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab